Dengue Epidemiology Forecast 2026-2035

Read more about this report - Request a Free Sample

Dengue Epidemiology Forecast Report Coverage

Expert Market Research's “Dengue Epidemiology Forecast Report 2026-2035” offers comprehensive information on the prevalence and demographics of dengue. It projects the future incidence and prevalence rates of dengue cases across various populations. The study covers age, gender, and type as major determinants of the dengue population. The report highlights patterns in the prevalence of dengue over time and projects future trends based on multiple variables.

Dengue Understanding: Disease Overview

Dengue is a mosquito-borne viral infection caused by any of four closely related dengue virus serotypes: DENV-1, DENV-2, DENV-3, and DENV-4. It is primarily transmitted to humans through the bite of infected Aedes aegypti or Aedes albopictus mosquitoes. After an incubation period of approximately 4–10 days, infected individuals may develop high fever, headache, pain behind the eyes, muscle and joint pain, nausea, vomiting, and rash. Clinical illness ranges from asymptomatic or mild dengue to severe dengue, which can cause plasma leakage, severe bleeding, shock, or organ impairment.

Key Report Insights

Dengue Epidemiology Perspective

The Dengue epidemiology division offers information on the patient pool from history to the present as well as the projected trend for each of the 8 major markets. Expert Market Research provides both current and predicted trends for the Dengue epidemiology scenario by examining a wide range of studies. Additionally, the report covers the diagnosed patient pool for Dengue and their trends. The data is broken down into specific categories, such as total prevalent cases in males and females, and total diagnosed cases across different age groups and patient pools.

Type-Specific Disease Burden and Epidemiology Analysis

Read more about this report - Request a Free Sample

Country-wise Dengue Epidemiology

The Dengue epidemiology data and findings for the United States, Germany, Spain, Italy, France, the United Kingdom, Japan, and India are also provided in the epidemiology section.

Key Market Gaps, Untapped Opportunities, and Emerging Growth Areas in the Regional Disease Epidemiology Landscape

Dengue epidemiology across the selected regions presents opportunities for improved early diagnosis, surveillance, and clinical case management. India continues to face a substantial endemic disease burden, creating demand for scalable diagnostic and surveillance capabilities. In contrast, the United States and United Kingdom face a growing need for rapid recognition of travel-associated dengue, while locally acquired transmission has emerged periodically in parts of Southern Europe. Expansion of molecular and antigen-based diagnostics, strengthened mosquito surveillance, improved outbreak monitoring, and digital disease-reporting systems represent important opportunities. Climate variability, urbanization, and increasing international travel may further expand areas requiring dengue preparedness.

Dengue: Treatment Overview

There is currently no specific antiviral treatment for dengue; management primarily focuses on symptom control, hydration, monitoring, and early recognition of complications. Patients with uncomplicated dengue are advised to rest, maintain adequate oral fluid intake, and use acetaminophen (paracetamol) for fever and pain. Aspirin and nonsteroidal anti-inflammatory drugs such as ibuprofen should be avoided because they can increase bleeding risk. Patients with warning signs require closer clinical monitoring and may need intravenous fluids, while severe dengue requires hospitalization and intensive supportive care to manage shock, bleeding, fluid imbalance, or organ involvement. Supportive care therefore remains the central treatment approach.

Key Questions Answered

• What is the current and projected burden of dengue across the 8 major markets?
• Which countries across the 8 major markets account for the highest dengue patient populations and fastest growth rates?
• What is the diagnosed versus undiagnosed patient population of dengue across key countries in the 8 major markets?
• Which countries demonstrate the largest gaps in screening, early diagnosis, and disease awareness of dengue across the 8 major markets?
• What are the major drivers contributing to the increasing burden of Dengue across the 8 major markets?
• How do major comorbidities and risk factors influence dengue epidemiology trends across the 8 major markets?
• What are the regional trends in advanced disease progression, treatment uptake, and patient management of dengue across the 8 major markets?
• Which patient segments represent the highest unmet clinical need in the dengue landscape across the 8 major markets?
• Which therapeutic areas linked to dengue are expected to witness the strongest growth opportunities across the 8 major markets?
• How is the dengue epidemiology landscape expected to evolve over the next 5 to 10 years across the 8 major markets?
• Which countries across the 8 major markets offer the most attractive market opportunities based on dengue epidemiology and healthcare infrastructure?
• Which epidemiological trends are expected to influence future drug development and market access strategies for dengue across the 8 major markets?

Scope of the Dengue Epidemiology Report

• The report covers a detailed analysis of signs and symptoms, causes, risk factors, pathophysiology, diagnosis, treatment options, and classification/types of dengue based on several factors.
• Dengue Epidemiology Forecast Report covers data for the eight major markets (the US, France, Germany, Italy, Spain, the UK, Japan, and India).
• The dengue report helps to identify the patient population, and the unmet needs are highlighted along with an assessment of the disease's risk and burden.

Related Reports

Dengue Testing Market

Antiviral Drugs Market